Search

Protagonist Therapeutics Inc

Закрыт

СекторЗдравоохранение

128.69 -5.64

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

127.02

Макс.

130.13

Ключевые показатели

By Trading Economics

Доход

159M

163M

Продажи

157M

213M

P/E

Средняя по отрасли

140.34

48.735

Прибыль на акцию

2.29

Рентабельность продаж

76.285

Сотрудники

141

EBITDA

163M

166M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+27.55% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

846M

9.4B

Предыдущая цена открытия

134.33

Предыдущая цена закрытия

128.69

Protagonist Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

16 окт. 2026 г., 20:02 UTC

Social Media

Protagonist Therapeutics Inc shares are sharply lower, diverging from a recent trend of higher daily closes, with unusually high market volume today.

15 окт. 2026 г., 19:46 UTC

Social Media
Correlated Moves

UBS has initiated a Buy rating on Protagonist Therapeutics Inc with a price target of $184, highlighting the commercial potential of PN-881.

14 окт. 2026 г., 20:07 UTC

Social Media

PTGX declines after Leerink initiates coverage with outperform rating.

13 окт. 2026 г., 20:02 UTC

Protagonist Therapeutics Inc shares fell sharply, diverging from recent upward momentum, with unusually high trading volume observed today.

12 окт. 2026 г., 20:06 UTC

News
Social Media

Protagonist Therapeutics receives a Buy rating from UBS with a $184 price target, while Leerink Partners sets an Outperform rating with a $190 target.

9 окт. 2026 г., 22:21 UTC

Protagonist Therapeutics Inc shares traded modestly lower during after-market hours on Friday after peaking shortly after the regular session ended.

8 окт. 2026 г., 20:07 UTC

Protagonist Therapeutics Inc shares fell amid a broadly lower market, trading near the lower end of its one-month range and below its 20-day moving average.

7 окт. 2026 г., 20:01 UTC

Social Media

Protagonist Therapeutics Inc is trading higher, influenced by gains in the Biotechnology sector, despite pulling back from earlier session highs and high market volume.

6 окт. 2026 г., 20:07 UTC

Protagonist Therapeutics Inc shares fell sharply, remaining near the lower end of their one-month range and below the 20-day moving average.

1 окт. 2026 г., 20:07 UTC

Protagonist Therapeutics Inc shares fell as the broader market continued its decline, marking four consecutive days of lower closes and remaining below the 20-day moving average.

30 сент. 2026 г., 20:07 UTC

Protagonist Therapeutics Inc shares fell sharply after peaking earlier in the day, finishing below its 20-day moving average and near the lower end of its one-month range.

29 сент. 2026 г., 19:15 UTC

Social Media

Protagonist Therapeutics Inc shares fell, now near the low end of their one-month range, despite a user reporting a price target in the low $130s.

25 сент. 2026 г., 19:51 UTC

Protagonist Therapeutics Inc shares are advancing significantly, showing strong upward momentum with notable trading activity since Thursday's close.

24 сент. 2026 г., 19:46 UTC

Protagonist Therapeutics Inc shares fell sharply, reaching a low before noon and trading significantly below its 20-day moving average amid ongoing biotechnology sector weakness.

23 сент. 2026 г., 20:02 UTC

Protagonist Therapeutics Inc shares fell sharply, continuing a decline since Tuesday, with trading volume unusually high and prices near the lower end of their one-month range.

18 сент. 2026 г., 20:06 UTC

Protagonist Therapeutics Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

17 сент. 2026 г., 19:46 UTC

Protagonist Therapeutics Inc shares are trading roughly flat, currently below their opening level and the 20-day moving average after three consecutive lower closes.

16 сент. 2026 г., 19:13 UTC

Protagonist Therapeutics Inc shares fell sharply amid a broader market decline, influenced by mixed economic data and cautious investor sentiment ahead of jobless claims.

15 сент. 2026 г., 20:07 UTC

Protagonist Therapeutics shares are lower amid broader market concerns, following a significant drop in the NY Empire State Manufacturing Index for September.

11 сент. 2026 г., 20:08 UTC

News

Protagonist Therapeutics shares are higher as CEO Dinesh V. Patel exercises options and sells over 70,000 shares, boosting investor sentiment.

9 сент. 2026 г., 20:07 UTC

News
Social Media

Protagonist Therapeutics announced a $300 million share repurchase program, but shares are trading lower during Wednesday's session after pulling back from an earlier high.

2 сент. 2026 г., 20:08 UTC

Social Media

Protagonist Therapeutics shares are lower despite Barclays setting a $180 price target following the approval of Mimrylo for polycythemia vera treatment.

1 сент. 2026 г., 19:36 UTC

News
Social Media

Protagonist Therapeutics shares are lower today, despite analysts raising price targets following the approval of Mimrylo. Barclays set a target of $180.

28 авг. 2026 г., 20:02 UTC

Protagonist Therapeutics Inc is declining during Friday's session, reversing earlier gains amid rising U.S. Treasury yields and broader market dynamics.

27 авг. 2026 г., 20:07 UTC

Protagonist Therapeutics Inc shares are lower during Thursday's session, continuing a decline since Wednesday amid broader market conditions and economic resilience signals.

26 авг. 2026 г., 20:08 UTC

Protagonist Therapeutics Inc shares are trading higher today. No specific news was identified to explain the movement amid mixed broader market conditions.

25 авг. 2026 г., 23:36 UTC

Protagonist Therapeutics Inc. sees modest gains in after-market trading amid a broader market backdrop of declining crude oil prices and easing geopolitical tensions.

24 авг. 2026 г., 20:06 UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

21 авг. 2026 г., 20:06 UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

20 авг. 2026 г., 19:31 UTC

Correlated Moves

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.

Сравнение c конкурентами

Изменение цены

Protagonist Therapeutics Inc Прогноз

Целевая цена

By TipRanks

27.55% рост

Прогноз на 12 месяцев

Средняя 174.167 USD  27.55%

Максимум 190 USD

Минимум 149 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для Protagonist Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

13 ratings

13

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat